Pharmacodynamics of ceftaroline against staphylococcus aureus studied in an in vitro pharmacokinetic model of infection

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 6, 2013, Pages 2451-2456

  MacGowan, Alasdair P ^a   Noel, Alan R ^a   Tomaselli, Sharon ^a   Bowker, Karen E ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTAROLINE;

ANTIBACTERIAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERIAL VIABILITY; BACTERIOSTASIS; DRUG HALF LIFE; IN VITRO STUDY; MAXIMUM PLASMA CONCENTRATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; STEADY STATE; VANCOMYCIN INTERMEDIATE STAPHYLOCOCCUS AUREUS;

ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; COLONY COUNT, MICROBIAL; HUMANS; METHICILLIN; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; MODELS, BIOLOGICAL; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

EID: 84877849969     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01386-12     Document Type: Article

References (22)

1. Forest Laboratories Inc. 2010. Full prescribing information. Teflaro 69-1020308-W-APR11. Forest Laboratories Inc, St. Louis, MO.
2. Jones RN, Mendes R, Sader HS. 2010. Ceftaroline activity against pathogens associated with complicated skin and skin structure infections: Results from an international surveillance study. J. Antimicrob. Chemother. 65(Suppl 4):iv17-iv31.
3. Karlowsky JA, Adam HJ, Decorby MR, Lagacé-Wiens PR, Hoban DJ, Zhanel GG. 2011. In vitro activity of ceftaroline against Gram-positive and Gram-negative pathogens isolated from patients in Canadian hospitals in 2009. Antimicrob. Agents Chemother. 55:2837-2846.
4. Saravolatz L, Pawlak J, Johnson L. 2010. In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycinintermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates. Antimicrob. Agents Chemother. 54:3027-3030.
5. Moisan HM, Pruneau M, Malouin F. 2010. Binding of ceftaroline to penicillin-binding problems of Staphylococcus aureus and Streptococcus pneumoniae. J. Antimicrob. Chemother. 65:713-716.
6. Drusano GL. 2010. Pharmacodynamics of ceftaroline fosamil for complicated skin and skin structure infection: Rationale for improved antimethicillin resistant Staphylococcus aureus activity. J. Antimicrob. Chemother. 65(Suppl 4):iv33-iv39.
7. MacGowan AP, Rogers CA, Holt HA, Bowker KE. 2003. Activities of moxifloxacin against, and emergence of resistance in, Streptococcus pneumoniae and Pseudomonas aeruginosa in an in vitro pharmacokinetic model. Antimicrob. Agents Chemother. 47:1088-1095.
8. British Society for Antimicrobial Chemotherapy Working Party. 2001. Antimicrobial susceptibility testing. J. Antimicrob. Chemother. 46(Suppl 51):5-16.
9. Clinical and Laboratory Standards Institute. 2005. Performance standards for antimicrobial susceptibility testing. CLSI document M100-516. Clinical and Laboratory Standards Institute, Wayne, PA.
10. MacGowan AP, Bowker KE, Noel AR. 2008. Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection. Antimicrob. Agents Chemother. 52:1401-1406.
11. Jones RN, Fritsche TR, Ge Y, Kaniga K, Sader HS. 2005. Evaluation of PP1-0903M (T91825), a novel cephalosporin: Bactericidal activity, effects of modifying in vitro testing parameters and optimisation of disc diffusion tests. J. Antimicrob. Chemother. 56:1047-1052.
12. Pankuch GA, Appelbaum PC. 2009. Postantibiotic effect of ceftaroline against Gram-positive organisms. Antimicrob. Agents Chemother. 53: 4537-4539.
13. Vogelman B, Gudmundsson S, Leggett J, Turnidge J, Ebert S, Craig WA. 1988. Correlation of antimicrobial pharmacokinetic parameters and therapeutic efficacy in an animal model. J. Infect. Dis. 158:831-847.
14. Craig WA, Andes DR. 2008. In vivo pharmacodynamics of ceftobiprole against multiple bacterial pathogens in murine thigh and lung infection models. Antimicrob. Agents Chemother. 52:3492-3496.
15. Andes D, WA Craig. 2006. Pharmacodynamics of a new cephalosporin, PPI-0903 (TAK 599), active against methicillin-resistant Staphylococcus aureus in murine thigh and lung infection models: Identification of an in vivo pharmacokinetic-pharmacodynamic target. Antimicrob. Agents Chemother. 50:1376-1383.
16. MacGowan AP, Noel AR, Tomaselli S, Elliott H, Bowker KE. 2011. Pharmacodynamics of razupenem (PZ601) studied in an in vitro pharmacokinetic model of infection. Antimicrob. Agents Chemother. 55:1436-1442.
17. Keel RA, Crandon JL, Nicolau DP. 2011. Efficacy of human simulated exposures of ceftaroline administered at 600 mg every 12 hours against phenotypically diverse Staphylococcus aureus isolates. Antimicrob. Agents Chemother. 55:4028-4032.
18. Vidaillac C, Leonard SN, Rybak MJ. 2009. In vitro activity of ceftaroline against methicillin-resistant Staphylococcus aureus and heterogeneous vancomycin-intermediate S. aureus in a hollow fiber model. Antimicrob. Agents Chemother. 53:4712-4717.
19. Zhanel GG, Rossnagel E, Nichol K, Cox L, Karlowsky JA, Zelenitsky S, Noreddin AM, Hoban DJ. 2011. Ceftaroline pharmacodynamic activity versus community associated and healthcare-associated methicillinresistant Staphylococcus aureus, hetero-resistant vancomycinintermediate S. aureus, vancomycin-intermediate S. aureus and vancomycin resistant S. aureus using an in vitro model. J. Antimicrob. Chemother. 66:1301-1305.
20. Kimko H, Xu X, Nandy P, Samtani MN, Strauss RS, Bagchi P, Noel GJ. 2009. Pharmacodynamic profiling of ceftobiprole for the treatment of complicated skin and skin structure infections. Antimicrob. Agents Chemother. 53:3371-3374.
21. Corey GR, Wilcox MH, Talbot GH, Thye D, Friedland D, Baculik T, CANVAS 1 Investigators. 2010. CANVAS 1: The first phase III, randomised, double linked study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J. Antimicrob. Chemother. 65(Suppl 4):iv41-iv51.
22. Wilcox MH, Corey GR, Talbot GH, Thye D, Friedland D, Baculik T, CANVAS 2 Investigators. 2010. CANVAS 2: The second phase III, randomised, double-blind, study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J. Antimicrob. Chemother. 65(Suppl 4):iv53-iv65.